Drug
Men16132
Men16132: highest development phase Phase 2, developed by Menarini. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Menarini
Trials
| Drug | Phase | Indication |
|---|---|---|
| MEN16132 - 0.125 mg NCT01091116 | Phase 2 | Osteoarthritis, Knee |
Latest
No recent events.
Follow Men16132 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.